Colorectal cancer management: strategies in drug delivery

References

• Sullivan BA, Noujaim M, Roper J. Cause, epidemiology, and histology of polyps and pathways to colorectal cancer. Gastrointest Endoscopy Clin N Am. 2022;32:177–194.
   PubMedGoogle Scholar
• Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA CANCER J CLIN. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Gulbake A, Jain A, Jain A, et al. Insight to drug delivery aspects for colorectal cancer. World J Gastroenterol. 2016;22:582–599.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Colorectal cancer facts & figures 2020-2022. Atlanta: American Cancer Society; 2020.
   Google Scholar
• Øines M, Helsingen LM, Bretthauer M, et al. Epidemiology and risk factors of colorectal polyps. Best Pract Res Clin Gastroenterol. 2017;31(4):419–424.
   PubMedGoogle Scholar
• [cited 2022 Jun 02]. https://www.cancer.net/cancer-types/colorectal-cancer/stages
   Google Scholar
• Swiderska M, Choromańska B, Dąbrowska E, et al. The diagnostics of colorectal cancer. Contemp Oncol (Pozn). 2014;18(1):1–6. Epub 2013 Dec 20. PMID: 24876814; PMCID: PMC4037991.
   PubMedGoogle Scholar
• Swiderska M, Choromańska B, Dąbrowska E, et al. The diagnostics of colorectal cancer. Contemp Oncol (Pozn). 2014;18(1):1–6.
   PubMedGoogle Scholar
• Lin C, Ng H, Pan W, et al. Exploring different strategies for efficient delivery of colorectal cancer therapy. Int J Mol Sci. 2015;16:26936–26952.
   PubMedGoogle Scholar
• van Eeghen EE, Bakker SD, van Bochove A, et al. High risk Stage 2 and Stage 3 colon cancer, predictors of recurrence and effect of adjuvant therapy in a nonselected population. Int Sch Res Not. 2015;2015:1–10. DOI:https://doi.org/10.1155/2015/790186
   Google Scholar
• Marshall JL, Haller DG, de Gramont A, et al. Adjuvant therapy for Stage II and III colon cancer: consensus report of the international society of gastrointestinal oncology. Gastrointest Cancer Res. 2007;1:146–154.
   PubMedGoogle Scholar
• Rathva B, Desai SV. Colorectal cancer: etiology, pathogenesis and current treatment. J Innovations Pharm Biol Sci. 2020;7(4):20–24.
   Google Scholar
• Sancho E, Batlle E, Clevers H. Signaling pathways in intestinal development and cancer. Annu Rev Cell Dev Biol. 2004;20(1):695–723.
   PubMedGoogle Scholar
• Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Sig Transduct Target Ther. 2020;5(22). DOI:https://doi.org/10.1038/s41392-020-0116-z.
   Google Scholar
• Yewale C, Baradia D, Patil S, et al. Docetaxel loaded immunonanoparticles delivery in EGFR over expressed breast carcinoma cells. J Drug Delivery Sci Technol. 2018;45:334–345.
   Web of Science ®Google Scholar
• Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54(6):295–308.
   PubMed Web of Science ®Google Scholar
• Bhatt P, Lalani R, Mashru R, et al. Abstract 2065: anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved & efficacy on ovarian cancer cells. Cancer Res. 2016;76(14 Supplement):2065.
   Google Scholar
• Vhora I, Patil S, Bhatt P, et al. Receptor- targeted drug delivery: current perspective and challenges. Ther Deliv. 2014;5(9):1007–1024.
   PubMedGoogle Scholar
• Byers T, Levin B, Rothenberger D, et al. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society detection and treatment advisory group on colorectal cancer. CA Cancer J Clin. 1997;47:154–160.
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–338.
   PubMed Web of Science ®Google Scholar
• Burz C, Berindan-Neagoe IB, Balacescu O, et al. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients. J Gastrointest Liver Dis. 2009;18:39–43.
   PubMedGoogle Scholar
• Comella P. A review of the role of capecitabine in the treatment of colorectal cancer. Ther Clin Risk Manag. 2007;3:421–431.
   PubMedGoogle Scholar
• Messerer CL, Ramsay EC, Waterhouse D, et al. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res. 2004;10:6638–6649.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Regorafenib: a Review in Metastatic Colorectal Cancer. Drugs. 2018;78:1133–1144.
   PubMedGoogle Scholar
• Amjad MT, Chidharla A, Kasi A. Cancer chemotherapy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [cited 2022 30 Jan]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564367/
   Google Scholar
• Faugeras L, Dili A, Druez A, et al. Treatment Options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy. Crit Rev Oncol Hematol. 2017;115:59–66.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial teatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–1417.
   PubMed Web of Science ®Google Scholar
• Liao M-Y, Lai J-K, Kuo MY-P, et al. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget. 2015;6:24947–24968.
   PubMedGoogle Scholar
• Gunturi A, McDermott DF. Nivolumab for the treatment of cancer. Expert Opin Investig Drugs. 2015;24:253–260.
   PubMed Web of Science ®Google Scholar
• Song H, Su C, Cui W, et al. Folic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery. Biomed Res Int. 2013;2013:1–6.
   Google Scholar
• Sabra R, Billa N. Soliciting the oral route as a logical approach to managing colon cancer. Front Bioeng Biotechnol. 2021;9. Article 645923. DOI:https://doi.org/10.3389/fbioe.2021.645923.
   Google Scholar
• Guo Y, Zong S, Pu Y, et al. Advances in pharmaceutical strategies enhancing the efficiencies of oral colon-targeted delivery systems in inflammatory bowel disease. Molecules. 2018 Jul;23(7):1622.
   PubMed Web of Science ®Google Scholar
• Ashford M, Fell J, Attwood D, et al. An evaluation of pectin as a carrier for drug targeting to the colon. J Control Release. 1993;26(3):213–220.
   Web of Science ®Google Scholar
• Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev TM Ther Drug Carrier Syst. 2001;18(5):433–458.
   PubMed Web of Science ®Google Scholar
• Maroni A, Zema L, Loreti G, et al. Film coatings for oral pulsatile release. Int J Pharm. 2013;457(2):362–371.
   PubMedGoogle Scholar
• Gazzaniga A, Iamartino P, Maffione G, et al. Oral delayed-release system for colonic specific delivery. Int J Pharm. 1994;108(1):77–83.
   Google Scholar
• Fukui E, Miyamura N, Uemura K, et al. Preparation of enteric coated timed- release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm. 2000;204(1–2):7–15.
   PubMed Web of Science ®Google Scholar
• Vassallo M, Camilleri M, Phillips SF, et al. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology. 1992;102(1):102–108.
   PubMedGoogle Scholar
• Mr von der O, Camilleri M, Kvols LK, et al. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med. 1993;329(15):1073–1078.
   PubMedGoogle Scholar
• Peeters R, Kinget R. Film-forming polymers for colonic drug delivery: i. Synthesis and physical and chemical properties of methyl derivatives of Eudragit S. Int J Pharm. 1993;94(1–3):125–134.
   Google Scholar
• Huang SJ, Bansleben DA, Knox JR. Biodegradable polymers: chymotrypsin degradation of a low molecular weight poly (ester-urea) containing phenylalanine. J Appl Polym Sci. 1979;23(2):429–437.
   Google Scholar
• Ratner BD, Gladhill KW, Horbett TA. Analysis of in vitro enzymatic and oxidative degradation of polyurethanes. J Biomed Mater Res. 1988;22(6):509–527.
   PubMedGoogle Scholar
• Hergenrother RW, Wabers HD, Cooper SL. The effect of chain extenders and stabilizers on the in-vivo stability of polyurethanes. J Appl Biomater. 1992;3(1):17–22.
   Google Scholar
• Friend DR, Chang GW. Drug glycosides: potential prodrugs for colon-specific drug delivery. J Med Chem. 1985;28(1):51–57.
   PubMedGoogle Scholar
• Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci. 2003;18(1):3–18.
   PubMed Web of Science ®Google Scholar
• Barclay TG, Day CM, Petrovsky N, et al. Review of polysaccharide particle-based functional drug delivery. Carbohydr Polym. 2019;221:94–112.
   PubMed Web of Science ®Google Scholar
• Takaya T, Niwa K, Muraoka M, et al. Importance of dissolution process on systemic availability of drugs delivered by colon delivery system. J Control Release. 1998;50(1–3):111–122.
   PubMedGoogle Scholar
• Muraoka M, Hu Z, Shimokawa T, et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J Control Release. 1998;52(1–2):119–129.
   PubMedGoogle Scholar
• Jeong Y-I, Ohno T, Hu Z, et al. Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method. J Control Release. 2001;71(2):175–182.
   PubMed Web of Science ®Google Scholar
• Hay DJ, Sharma H, Irving MH. Spread of steroid-containing foam after intrarectal administration. Br Med J. 1979;1(6180):1751–1753.
   PubMedGoogle Scholar
• Watanabe S, Kawai H, Katsuma M, et al. Colon-specific drug release system. Google Patents; 2002.
   Google Scholar
• Katsuma M, Watanabe S, Takemura S, et al. Scintigraphic evaluation of a novel colon-targeted delivery system (CODESTM) in healthy volunteers. J Pharm Sci. 2004;93(5):1287–1299.
   PubMed Web of Science ®Google Scholar
• Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm. 2002;235(1–2):1–15.
   PubMed Web of Science ®Google Scholar
• Swanson DR, Barclay BL, Wong PS, et al. Nifedipine gastrointestinal therapeutic system. Am J Med. 1987;83(6):3–9.
   PubMedGoogle Scholar
• Muro S. Challenges in design and characterization of ligand-targeted drug delivery systems. J Control Release. 2012 Dec 10;164(2):125–137.
   PubMed Web of Science ®Google Scholar
• Schneider-Futschik EK, Reyes-Ortega F. Advantages and disadvantages of using magnetic nanoparticles for the treatment of complicated ocular disorders. Pharmaceutics. 2021;13(8):1157.
   PubMedGoogle Scholar
• Grifantini R, Taranta M, Gherardini L, et al. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer. J Control Release. 2018;280:76–86.
   PubMed Web of Science ®Google Scholar
• Liu F, Moreno P, Basit AW. A novel double-coating approach for improved pH- triggered delivery to the ileo-colonic region of the gastrointestinal tract. Eur J Pharm Biopharm. 2010 Feb 1;74(2):311–315.
   PubMedGoogle Scholar
• Mutalik S, Suthar NA, Managuli RS, et al. Development and performance evaluation of novel nanoparticles of a grafted copolymer loaded with curcumin. Int J Biol Macromol. 2016 1;86:709–720.
   PubMed Web of Science ®Google Scholar
• Sahu KK, Pandey RS. Development and characterization of HBsAg-loaded Eudragit nanoparticles for effective colonic immunization. Pharm Dev Technol. 2019 Feb 7;24(2):166–175.
   PubMed Web of Science ®Google Scholar
• Foppoli A, Maroni A, Moutaharrik S, et al. In vitro and human pharmacoscintigraphic evaluation of an oral 5-ASA delivery system for colonic release. Int J Pharm. 2019 Dec 15;572:118723.
   PubMedGoogle Scholar
• Song Q, Jia J, Niu X, et al. An oral drug delivery system with programmed drug release and imaging properties for orthotopic colon cancer therapy. Nanoscale. 2019;11(34):15958–15970.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Xu X, Gong J, et al. Fabrication of chitosan-coated konjac glucomannan/sodium alginate/graphene oxide microspheres with enhanced colon-targeted delivery. Int J Biol Macromol. 2019 Jun 15;131:209–217.
   PubMed Web of Science ®Google Scholar
• Gautam M, Santhiya D. In-situ mineralization of calcium carbonate in pectin based edible hydrogel for the delivery of protein at colon. J Drug Delivery Sci Technol. 2019 Oct 1;53:101137.
   Google Scholar
• Guo F, Ouyang T, Peng T, et al. Enhanced oral absorption of insulin using colon-specific nanoparticles co-modified with amphiphilic chitosan derivatives and cell-penetrating peptides. Biomater Sci. 2019;7(4):1493–1506.
   PubMedGoogle Scholar
• Teruel AH, Pérez-Esteve É, Gonzalez-Alvarez I, et al. Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: new approaches for inflammatory bowel diseases treatment. J Control Release. 2018 Jul 10;281:58–69.
   PubMedGoogle Scholar
• Yu B, Tai HC, Xue W, et al. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Member Biol. 2010;27:286–298.
   PubMed Web of Science ®Google Scholar
• Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153:198–205.
   PubMed Web of Science ®Google Scholar
• Kosmidis C, Zarogoulidis P, Efthimidis G, et al. Colorectal cancer from molecular pathways to gene therapy. Oncomedicine. 2017;2:93–101.
   Google Scholar
• Takegawa N, Yonesaka K. HER2 as an emerging oncotarget for colorectal cancer treatment after failure of anti-epidermal growth factor receptor therapy. Clin Colorectal Cancer. 2017;16:247–251.
   PubMed Web of Science ®Google Scholar
• Xie, Xie Y-H, Chen Y-X, et al. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:22.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Ueda J, Ishiwata T. Fibroblast growth factor receptor 2: expression, roles, and potential as a novel molecular target for colorectal cancer. Patholog Res Int. 2012;2012:1–8. Article ID 574768, 8 Pages.
   Google Scholar
• Sahin IH, Klostergaard J. CD44 as a drug delivery target in human cancers: where are we now? Expert Opin Ther Targets. 2015;19(12):1587–1591.
   PubMed Web of Science ®Google Scholar
• Sheng J, Sun H, Yu FB, et al. The role of Cyclooxygenase-2 in colorectal cancer. Int J Med Sci. 2020;17(8):1095–1101.
   PubMedGoogle Scholar
• Pardini B, Kumar R, Naccarati A, et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol. 2011;72(1):162–163.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Verma RS, Murugesan R, et al. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today. 2017;22:1224–1232.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK, Ganesh N, et al. Design and development of ligand- appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomed Nanotechnol Biol Med. 2010;6:179–190.
   PubMed Web of Science ®Google Scholar
• Bahrami B, Hojjat-Farsangi M, Mohammadi H, et al. Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett. 2017;190:64–83.
   PubMed Web of Science ®Google Scholar
• Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26:64–70.
   PubMed Web of Science ®Google Scholar
• Ying K, Bai B, Gao X, et al. Orally administrable therapeutic nanoparticles for the treatment of colorectal cancer. Front Bioeng Biotechnol. 2021;9:670124.
   PubMedGoogle Scholar
• Sharma N, Purwar N, Gupta PC, et al. Microspheres as drug carriers for controlled drug delivery: a review. Int J Pharm Sci Res. 2015;6(11):4579–4587.
   Google Scholar
• Dhadde GS, Mali HS, Raut ID, et al. A review on microspheres: types, method of preparation, characterization and application. Asian J Pharm Technol. 2021;11(2):1–7.
   Google Scholar
• Jena GK, Patra CN, Panigrahi KC, et al. Design, optimization, and evaluation of capecitabine-loaded chitosan microspheres for colon targeting. Asian J Pharm. 2017;11:S592–S602.
   Google Scholar
• Patel N, Desai J, Kumar P, et al. Development and in vitro characterization of capecitabine-loaded alginate-pectinate-chitosan beads for colon targeting. J Macromol Sci Part B Phys. 2016;55:33–54.
   Web of Science ®Google Scholar
• Urbanska AM, Karagiannis ED, Guajardo G, et al. Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer. Biomaterials. 2012;33:4752–4761.
   PubMedGoogle Scholar
• Sureshkumar R, Munikumar, Ganesh GNK, et al. Formulation and evaluation of pectin- hydroxypropyl methylcellulose coated curcumin pellets for colon delivery. Asian J Pharm. 2009;3:138.
   Google Scholar
• Vajpayee A, Fartyal S, Pratap A, et al. Formulation and evaluation of colon targeted curcumin microspheres using natural polymers. J Pharm Res Opin. 2011;4:108–112.
   Google Scholar
• Ganguly K, Kulkarni AR, Aminabhavi TM. In vitro cytotoxicity and in vivo efficacy of 5-fluorouracil-loaded enteric-coated PEG-cross-linked chitosan microspheres in colorectal cancer therapy in rats. Drug Deliv. 2016;23:2838–2851.
   PubMed Web of Science ®Google Scholar
• Jithan A, Madhavi M, Madhavi K. Preparation and in vitro/in vivo characterization of curcumin microspheres intended to treat colon cancer. J Pharm Bioallied Sci. 2012;4:164.
   PubMedGoogle Scholar
• Majumder N, G Das N, Das SK. Polymeric micelles for anticancer drug delivery. Ther Deliv. 2020 Oct;11(10):613–635.
   PubMed Web of Science ®Google Scholar
• Yun Q, Wang SS, Xu S, et al. Use of 5-fluorouracil loaded micelles and cisplatin in thermosensitive chitosan hydrogel as an efficient therapy against colorectal peritoneal carcinomatosis. Macromol Biosci. 2017;17(4):1600262.
   Web of Science ®Google Scholar
• Wang K, Zhang T, Liu L, et al. Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. Int J Nanomedicine. 2012;7:4487–4497.
   PubMed Web of Science ®Google Scholar
• Birgani MT, Erfani MV, Babaei E, et al. Dendrosomal nano-curcumin, the novel formulation to improve the anticancer properties of curcumin. Pbiosci.Ut.Ac.Ir. 2015;5:143–158.
   Google Scholar
• Parvanian S, Mojtaba S, Aghashiri M. Sensing and bio-sensing research multifunctional nanoparticle developments in cancer diagnosis and treatment, sens. Bio Sens Res. 2017;13:81–87.
   Google Scholar
• Hassanzadeganroudsari M. Development and characterization of targeted nanoparticles loaded with Oxaliplatin for colorectal cancer treatment. J Nanomed Nanotechnol. 2018;2018(9). DOI: https://doi.org/10.4172/2157-7439-C5–080.
   Google Scholar
• Tummala S, Satish Kumar MN, Prakash A. Formulation and characterization of 5- Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J. 2015;23:308–314.
   PubMed Web of Science ®Google Scholar
• Narmani A, Kamali M, Amini B, et al. Targeting delivery of oxaliplatin with smart PEG-modified PAMAM G4 to colorectal cell line. In vitro studies. Process Biochem. 2018;69:178–187.
   Web of Science ®Google Scholar
• Tawfik E, Ahamed M, Almalik A, et al. Prolonged exposure of colon cancer cells to 5-fluorouracil nanoparticles improves its anticancer activity. Saudi Pharm J. 2017;25:206–213.
   PubMed Web of Science ®Google Scholar
• Melguizo C, Delgado ÁV, Arias JL, et al. Folic acid- decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. Int J Pharm. 2016;516:61–70.
   PubMedGoogle Scholar
• Pandey S, Vijayendra Swamy S, Bhandari A, et al. Design development and statistical optimization of capecitabine loaded ph sensitive nanoparticle for colon targeted delivery: cell line study. Int J Pharm Res. 2015;7:71–79.
   Google Scholar
• Liu G, Wang M, He H, et al. Doxorubicin-loaded tumor-targeting peptide- decorated polypeptide nanoparticles for treating primary orthotopic colon cancer. Front Pharmacol. 2021;12:744811.
   PubMedGoogle Scholar
• Yu T, Wu C, Zhu C, et al. Oral administration of Liposome-Apatinib and locally delivery of docetaxel/MPEG-PCL by Fibrin glue synergistically improve therapeutic effect in colorectal cance. J Biomed Nanotechnol. 2018;14(12):2077–2091.
   PubMedGoogle Scholar
• Yang C, Liu HZ, Fu ZX, et al. Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma. BMC Biotechnol. 2011;11:21.
   PubMed Web of Science ®Google Scholar
• Handali S, Moghimipour E, Rezaei M, et al. A novel 5-Fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes. Biomed Pharmacother. 2018 Dec 1;108:1259–1273.
   PubMed Web of Science ®Google Scholar
• Ekambaram P, Sathali AH, Priyanka K, et al. Solid Lipid Nanoparticles: a review. Sci Revs Chem Commun. 2012;2(1):81–102.
   Google Scholar
• Rajpoot K, Jain SK. Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation. Artif Cells Nanomed Biotechnol. 2018;46(6):1236–1247.
   PubMed Web of Science ®Google Scholar
• Dudhipala N, Puchchakayala G. Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. Drug Dev Ind Pharm. 2018 Oct;44(10):1572–1582. Epub 2018 Jul 4. PMID: 29493289.
   PubMed Web of Science ®Google Scholar
• Serini S, Cassano R, Corsetto PA, et al. Omega-3 PUFA loaded in resveratrol-based solid lipid nanoparticles: physicochemical properties and antineoplastic activities in human colorectal cancer cells in vitro. Int J Mol Sci. 2018;19(2):586. Published 2018 Feb 16.
   Web of Science ®Google Scholar
• Krstić M, Medarević D, Đuriš J, et al. Chapter 12 - Self-nanoemulsifying drug delivery systems (SNEDDS) and self-microemulsifying drug delivery systems (SMEDDS) as lipid nanocarriers for improving dissolution rate and bioavailability of poorly soluble drugs. In: Grumezescu AM, editor. Lipid nanocarriers for drug targeting. Elsevier Inc.; 2018. p. 473–508.
   Google Scholar
• Soe ZC, Poudel BK, Nguyen HT, et al. Folate-targeted nanostructured chitosan/chondroitin sulfate complex carriers for enhanced delivery of bortezomib to colorectal cancer cells. Asian J Pharm Sci. 2019;14:40–51.
   PubMed Web of Science ®Google Scholar
• Izham MNM, Hussin Y, Aziz MNM, et al. Rasedee abdullah and noorjahan banu alitheen. Preparation and characterization of self nano-emulsifying drug delivery system loaded with citral and its antiproliferative effect on colorectal cells in vitro. Nanomaterials. 2019;9:1028.
   Web of Science ®Google Scholar
• Zhanga X, Zhao M, Cao N, et al. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment. Biomater Sci. 2020;8:1885–1896.
   PubMedGoogle Scholar
• Alibolandi M, Abnous K, Anvari S, et al. CD133-targeted delivery of self- assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer. Artif Cells Nanomed Biotechnol. 2018;46(sup1):1159–1169.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Vyas RB, Lad C, et al. A review on microsponge drug delivery system. J Drug Delivery Ther. 2014;4(5):29–35.
   Google Scholar
• Othman MH, Zayed GM, El Sokkary GH, et al. Preparation and evaluation of 5-fluorouracil loaded microsponges for treatment of colon cancer. J Cancer Sci Ther. 2017;9. DOI:https://doi.org/10.4172/1948-5956.1000433.
   Google Scholar
• Ali AU, El-Badry M, Elfaham T, et al. Formulation of 5-fluorouracil microsponges as colon targeted delivery system using 32 factorial design. Bull Pharm Sci Assiut Univ. 2018;41:31–44.
   Google Scholar
• Gupta A, Tiwari G, Tiwari R, et al. Enteric coated HPMC capsules plugged with 5-FU loaded microsponges: a potential approach for treatment of colon cancer. Braz J Pharm Sci. 2015;51(3):591–605.
   Google Scholar
• Flores SE, Rial-Hermida MI, Ramirez JC, et al. Microemulsions for colorectal cancer treatments. General considerations and formulation of methotrexate. Mini Rev Med Chem. 2016;16(6):498–508. PMID: 26349496.
   PubMedGoogle Scholar
• Wang L-L, Zheng W, Han Y, et al. In situ delivery of thermosensitive gel-mediated 5-fluorouracil microemulsion for the treatment of colorectal cancer. Drug Des Devel Ther. 2016;10:2855–2867.
   PubMed Web of Science ®Google Scholar
• Al-Karaki R, Awadallah A, Tawfeek HM, et al. Preparation, characterization and cytotoxic activity of new oleuropein microemulsion against hct-116 colon cancer cells. Pharm Chem J. 2020;53:1118–1121.
   Web of Science ®Google Scholar
• Chen YC, Chen BH. Preparation of curcuminoid microemulsions from Curcuma longa L. to enhance inhibition effects on growth of colon cancer cells HT- 29. RSC Adv. 2018;8:2323–2337.
   PubMedGoogle Scholar
• Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery. 2021;20:101–124.
   PubMed Web of Science ®Google Scholar
• Susan H, de Matos Maria BC, Metselaar JM, et al. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9. Article 790. DOI:https://doi.org/10.3389/fphar.2018.00790.
   Google Scholar
• Overman MJ, Kopetz S, McDermott RS, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): checkMate- 142 interim results. J Clin Oncol. 2018;34:3501.
   Google Scholar
• Aparicio T. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. Colon Rectum. 2011;5:33–35.
   Google Scholar
• Doi Y, Okada T, Matsumoto H, et al. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol- coated liposome improves antitumor activity in a murine colorectal tumor model. Cancer Sci. 2010;101:2470–2475.
   PubMed Web of Science ®Google Scholar
• Zalba S, Koning G, Navarro I, et al. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J Control Release. 2015;210:26–38.
   PubMed Web of Science ®Google Scholar
• Kadowaki S, Masuishi T, Ura T, et al. A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a phase 1 dose finding study. J Clin Oncol. 2019;36:856.
   Google Scholar
• Park YS, Lim HY, Lee J, et al. A randomized phase III study of sox (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer. J Clin Oncol. 2017;29:3524.
   Google Scholar
• Satoh T, Denda T, Hamaguchi T, et al. A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;35:707.
   Google Scholar
• Ma CJ, Huang CW, Chang TK, et al. Oncologic outcomes in metastatic colorectal cancer with regorafenib with FOLFIRI as a Third- or Fourth-Line Setting. Transl Oncol. 2019;12:502–512.
   PubMed Web of Science ®Google Scholar
• Shitara K, Yamanaka T, Denda T, et al. Reverce: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan. J Clin Oncol. 2019;36:557.
   Google Scholar
• Price TJ, Newhall K, Peeters M, et al. Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;33:740.
   Google Scholar
• Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077–1085.
   PubMed Web of Science ®Google Scholar
• Antonuzzo L, Giommoni E, Pastorelli D, et al. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: the OBELIX study. World J Gastroenterol. 2015;21:7281–7288.
   PubMedGoogle Scholar
• Sharma S, Abhyankar V, Burgess RE, et al. A phase I study of axitinib (AG- 013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol. 2010;21:297–304.
   PubMed Web of Science ®Google Scholar
• Patel BB, Sengupta R, Qazi S, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF- 1R. Int J Cancer. 2008;122:267–273.
   PubMed Web of Science ®Google Scholar
• Clinicaltrails.gov [Internet]. (US); 2022 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02912559
   Google Scholar
• Clinicaltrails.gov [Internet]. Massachusetts (US); 2021 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03144804
   Google Scholar
• Clinicaltrails.gov [Internet]. Berlin (Germany). 2018 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02519582
   Google Scholar
• Clinicaltrails.gov [Internet]. Minnesota, New York, North Carolina, Pennsylvania (US); 2021 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02466009
   Google Scholar
• Clinicaltrails.gov [Internet]. Shanghai (China); 2019 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03329183
   Google Scholar
• Clinicaltrails.gov [Internet]. North Carolina (US); 2021 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02008383
   Google Scholar
• Clinicaltrails.gov [Internet]. Islamic Republic (Iran); 2018 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03391934
   Google Scholar
• Clinicaltrails.gov [Internet]. Texas (US); 2019 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03087071
   Google Scholar
• Clinicaltrails.gov [Internet]. Hubei (China); 2017 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03210064
   Google Scholar
• Clinicaltrails.gov [Internet]. (Cyprus, Greece); 2021 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03311750
   Google Scholar
• Clinicaltrails.gov [Internet]. Austria, France, Germany, Hungary, Italy, Spain, (UK); 2021 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02848443
   Google Scholar
• Clinicaltrails.gov [Internet]. Liaoning (China); 2017 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03053167
   Google Scholar
• Clinicaltrails.gov [Internet]. Massachusetts (US); 2021 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03668431
   Google Scholar
• Clinicaltrails.gov [Internet]. (Germany); 2022 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03520946
   Google Scholar
• Clinicaltrails.gov [Internet]. Shanghai (China); 2021 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03727763
   Google Scholar
• Clinicaltrails.gov [Internet]. Madrid (Spain); 2022 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03635021
   Google Scholar
• Clinicaltrails.gov [Internet]. Guangdong (China); 2020 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03638297
   Google Scholar
• Clinicaltrails.gov [Internet]. Henan (China); 2020 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03397199
   Google Scholar
• Clinicaltrails.gov [Internet]. (Belgium, Czechia). 2022 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03799731
   Google Scholar
• Clinicaltrails.gov [Internet]. Dijon (France); 2019 [cited 2022 May 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03795311
   Google Scholar